• In Landmark Ruling, Indian Generics Manufacturer Obtains Compulsory License

    In a landmark ruling, the Indian Patent Office (IPO) has granted generics manufacturer Natco a compulsory license to manufacture Bayer's oncology drug Nexavar, reports Pharmalot . The 9 March ruling has the could revolutionize the pharmaceutical industry in India by potentially allowing any number of generic manufacturers to challenge patented medicines so long as they pay royalties to the original manufacturer and seek to lower the price of the drug in order to make it...
  • NBC Investigation 'Raises Questions About Lax Regulatory Oversight'

    An investigation by Dateline NBC has found that clinical trial compensation in India is often driving economically disadvantaged patients to enroll in the trials regardless of the risks to their own safety. According to the Indian government, more than 1,500 Indians have died as a result of clinical trial participation since 2008. This number is likely far lower than the actual number, as "official documentation of the deaths is frequently incomplete or non-existent," ...